Percentage of patients presenting with AJCC Stage Group 0, I, II, or III disease, who undergo a needle biopsy to establish diagnosis of breast cancer.
- Measure TypeElectronic Clinical Quality Measure (eCQM)Level Of AnalysisCare SettingNumerator
Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer.
DenominatorWomen with AJCC Stage 0, I, II, or II breast cancer undergoing surgery:
• Women
• Age >=18 at time of diagnosis
• Primary tumors of the breast
• Epithelial invasive malignancy only
• Diagnosis and all or part of first course of treatment performed at the reporting facilityExclusionsExclusions:
Men; not a first or only cancer diagnosis; non-epithelial tumors; metastatic disease (AJCC Stage IV); phyllodes tumor histology (9020);
Patient refused biopsy,
Patient medically unable to hold position for image guided biopsy,
Patient requires sub-arolar excision for nipple discharge,
Lesion too superficial,
Breast too small,
Lesion inaccessible by needle biopsy,
Cancer found in prophylactic mastectomy,
Benign high risk lesion diagnosed by needle biopsy, requiring excisional biopsy
Discordant biopsy results compared to suspicious imagingTesting Data Sources
- Measure StructureClinical Condition Topic AreaNon Condition SpecificTarget PopulationNational Quality Strategy PrioritiesEffective Communication and Care Coordination
- Risk Adjustment
- Current or planned use(s)
- Most Recent Endorsement ActivityMeasure Retired and Endorsement Removed Cancer Project 2015-2016Initial EndorsementEndorsement StatusLast UpdatedRemoval Date
- StewardSteward Organization Email